Sinus bradycardia is a cardiac rhythm disorder characterized by a heart rate of less than 60 beats per minute (bpm), originating from the normal electrical activity of the sinoatrial node. In many cases, it represents a physiological variant, such as in athletes or during sleep, while in other situations it may be the manifestation of an underlying pathology.
The distinction between physiological sinus bradycardia and pathological sinus bradycardia is fundamental for clinical management. The former is observed in healthy individuals with high vagal tone, in the absence of symptoms or structural cardiac abnormalities. The latter may derive from sinoatrial node dysfunction, metabolic, neurological, or cardiovascular diseases, with possible hemodynamic consequences and need for treatment.
Etiology
The causes of sinus bradycardia can be classified as intrinsic, when stemming from structural damage to the sinoatrial node, and extrinsic, when depending on external factors that modulate the activity of the cardiac pacemaker.
Intrinsic causes (direct damage to the sinoatrial node):
Idiopathic fibrotic degeneration: aging may lead to progressive fibrotic replacement of the sinoatrial node, reducing the number of pacemaker cells and consequently slowing impulse generation.
Ischemic heart disease: reduced blood supply to the sinoatrial node, as in inferior myocardial infarction, can alter its automatism.
Infiltrative diseases: conditions such as amyloidosis and sarcoidosis may compromise conduction tissue and alter electrical impulse transmission.
Genetic channelopathies: mutations affecting ion channels involved in sinoatrial node depolarization can predispose to reduced cardiac pacemaker activity.
Extrinsic causes (functional alterations of the sinoatrial node):
Transient metabolic imbalances: conditions such as severe hypothyroidism (reduced basal metabolism), hyperkalemia (altered membrane potential of pacemaker cells), and hypothermia (slowed impulse generation) can cause sinus bradycardia.
Bradycardic drugs: beta-blockers, non-dihydropyridine calcium channel blockers, class III antiarrhythmics, and digoxin can depress sinoatrial node automatism.
Neurological dysfunctions: conditions such as carotid sinus hypersensitivity syndrome and autonomic neuropathies (e.g., diabetic neuropathy) may alter heart rate regulation, causing pathological sinus bradycardia.
Pathogenesis and Pathophysiology
Sinus bradycardia is caused by a reduction in the spontaneous discharge frequency of the sinoatrial node. This can occur through three main mechanisms:
Reduction of sinus automatism: the spontaneous depolarization of sinoatrial node pacemaker cells is slowed, resulting in reduced heart rate. This phenomenon may be linked to primary node degeneration, ischemia, or metabolic dysfunctions.
Increased vagal influence: excessive parasympathetic stimulation (mediated by the vagus nerve) inhibits sinoatrial node depolarization, slowing its activity. This is typical of physiological sinus bradycardia in athletes but can also be pathological in conditions of carotid sinus hypersensitivity.
Pharmacological and metabolic effects: bradycardic drugs and metabolic alterations such as hypothyroidism and hyperkalemia may negatively modulate the electrical activity of the sinoatrial node, slowing impulse generation.
From a pathophysiological perspective, sinus bradycardia can have variable consequences. In mild and physiological forms, the reduction in heart rate is well compensated by an increase in stroke volume. However, in more marked forms or in the presence of sinoatrial node dysfunction, the slowing of heart rate can impair organ perfusion, causing hypotension, syncope, and reduced exercise tolerance.
Risk Factors
Risk factors increase the likelihood of developing pathological sinus bradycardia, although they are not direct causes. Some subjects may have physiological sinus bradycardia, but in the presence of certain predisposing factors, the risk of developing symptoms or progressing to sinoatrial node dysfunction increases. The main risk factors are:
Advanced age: with advancing age, sinoatrial node degeneration becomes more pronounced, increasing the risk of pathological reduction of cardiac automatism.
Cardiovascular diseases: conditions such as ischemic heart disease, heart failure, and left ventricular hypertrophy may contribute to the development of pathological sinus bradycardia.
Chronic use of bradycardic drugs: prolonged use of beta-blockers, non-dihydropyridine calcium antagonists, and antiarrhythmics may favor the onset of clinically significant bradycardia.
Chronic metabolic imbalances: mild or untreated hypothyroidism and persistent electrolyte alterations, such as chronic hyperkalemia, may predispose to progressive reduction of sinus automatism.
Constitutional high vagal tone: subjects with marked parasympathetic activity at rest may develop more pronounced sinus bradycardia, especially in response to vagal stimuli (e.g., carotid sinus reflex, stressful situations).
Neurological dysautonomias: diseases of the autonomic system, such as diabetic neuropathy and Shy-Drager syndrome, may alter heart rate regulation.
Early recognition of these risk factors is essential to distinguish benign from potentially pathological forms and prevent possible complications.
Clinical Manifestations
The symptomatology of sinus bradycardia varies according to the severity of heart rate reduction and the cardiovascular system’s ability to compensate for the chronotropic deficit. Many patients with mild sinus bradycardia are asymptomatic, especially if the heart rate remains above 50 bpm. However, in more marked forms or in subjects with cardiovascular compromise, significant signs and symptoms may appear.
Symptoms reported by the patient:
Asthenia and fatigue: related to reduced muscular and cerebral perfusion.
Dizziness and presyncope: caused by cerebral hypoperfusion.
Syncope: in more severe cases, with very low heart rate and cerebral hypoperfusion.
Exertional dyspnea: due to the heart’s inability to adequately increase cardiac output.
Exercise intolerance: caused by the limited ability to increase heart rate during physical activity.
Palpitations: the patient may perceive irregular beats or pauses, especially if arrhythmias coexist.
Clinical signs observable on physical examination:
Obvious bradycardia: heart rate below 60 bpm, often below 50 bpm in more marked forms.
Hypotension: in cases where bradycardia compromises cardiac output.
Pallor and peripheral hypoperfusion: signs of reduced systemic perfusion.
Dependent edema: in cases where bradycardia contributes to venous congestion.
Altered sensorium: transient confusion state in patients with cerebral hypoperfusion.
Patients with severe sinus bradycardia have a high risk of syncopal episodes, with possible traumatic consequences. In subjects with underlying heart disease, bradycardia may worsen heart failure and predispose to ventricular arrhythmias.
Diagnosis
The diagnosis of sinus bradycardia is based on a complete clinical evaluation and instrumental confirmation by ECG. The goal is to identify the underlying cause, assess the clinical significance of the bradycardia, and determine the need for treatment.
Physical examination and medical history
Detection of a reduced heart rate by auscultation or pulse palpation is the first step. However, to distinguish physiological from pathological bradycardia, it is necessary to evaluate the clinical context. A detailed history is fundamental to identify any associated symptoms, the use of bradycardic drugs, and the presence of predisposing conditions.
Electrocardiogram (ECG)
The ECG is the fundamental test to confirm diagnosis and characterize the type of sinus bradycardia. It may show:
Regular sinus rhythm with a rate below 60 bpm.
Prolonged PP interval with normal AV conduction.
Sinus pause in cases with transient reduction of sinoatrial node activity.
Prolonged electrocardiographic monitoring
In cases where bradycardia is intermittent, prolonged monitoring is indicated to identify and characterize episodes of bradycardia.
24-48 hour Holter ECG: useful to document paroxysmal bradycardias and correlate symptoms with heart rhythm.
Implantable loop recorder: indicated in patients with unexplained syncope and suspected paroxysmal sinus bradycardia.
Functional tests and further investigations
In patients suspected of having a dysautonomic or vagal origin of bradycardia, functional tests may be indicated to evaluate autonomic tone and chronotropic response.
Tilt test: useful in patients with suspected vagal hypersensitivity bradycardia or vasovagal syncope.
Exercise testing: evaluates the chronotropic response in patients with exercise intolerance.
Electrophysiological study (EPS): indicated in patients with suspected advanced sinoatrial node dysfunction.
An accurate diagnosis allows distinction between physiological and pathological forms and identification of patients needing specific treatment.
Treatment and Prognosis
Treatment of sinus bradycardia depends on the underlying cause, the severity of symptoms, and any hemodynamic compromise. In physiological or asymptomatic forms, often no intervention is required, while symptomatic cases may need targeted therapy.
Management of physiological forms
In healthy subjects, such as athletes or young people with high vagal tone, sinus bradycardia does not require treatment. However, it is important to monitor for any signs of progression to sinoatrial node dysfunction in at-risk patients.
Treatment of pathological forms
Modification of drug therapy: in patients treated with beta-blockers, calcium antagonists, or antiarrhythmics, dose reduction or suspension may improve heart rate.
Correction of metabolic alterations: treatment of hypothyroidism, hyperkalemia, or hypothermia may normalize heart rate in cases secondary to metabolic imbalances.
Pharmacological stimulation: in acute cases, drugs such as atropine (muscarinic antagonist) can temporarily increase heart rate.
Pacing device implantation: indicated in patients with severe, symptomatic sinus bradycardia unresponsive to other therapies, especially in the presence of sinoatrial node dysfunction with prolonged pauses.
Prognosis
The prognosis of sinus bradycardia varies based on the cause and presence of symptoms. Benign forms do not entail significant risks and do not require specific treatments. However, in pathological forms associated with sinoatrial node dysfunction, the risk of syncope, heart failure, and pacing needs increases over time.
Complications
Sinus bradycardia may be well tolerated or, in some cases, cause potentially serious complications, especially in patients with hemodynamic compromise. The main complications include:
Syncope and falls: marked bradycardia may cause syncopal episodes with risk of trauma.
Exercise intolerance: the reduced ability to increase heart rate limits cardiovascular adaptation to physical activity.
Heart failure: in patients with heart failure, bradycardia may worsen symptoms and reduce chronotropic reserve.
Cardiac arrhythmias: bradycardia can promote ventricular arrhythmias, such as torsades de pointes, in patients with predisposing conditions.
Careful monitoring and appropriate treatment are fundamental to prevent complications and improve quality of life in patients affected by pathological sinus bradycardia.
Bibliography
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948.
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay. Journal of the American College of Cardiology. 2019;74(7):932-987.
Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Circulation. 2017;136(5):e60-e122.
Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation. 2008;117(21):e350-e408.
Semelka M, Gera J, Usman S. Sick sinus syndrome: a review. American Family Physician. 2013;87(10):691-696.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
Alboni P, Alboni M. Vasovagal syncope as a mythological syndrome: a critical review of a wide-spread entity. Journal of Arrhythmia. 2022;38(1):76-84.
Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on the Evaluation of Syncope. Circulation. 2008;118(8):850-878.
Wang TJ, Larson MG, Levy D, et al. Impact of Obesity on Electrocardiographic Left Ventricular Hypertrophy. Journal of the American College of Cardiology. 2004;43(6):1046-1051.
